

New Insights Into Aortic Diseases

A Report From the Third International Meeting on Aortic Diseases (IMAD3)

Helena Kuivaniemi^{1*}, Natzi Sakalihasan², Frank A. Lederle⁴, Gregory T. Jones⁵, Jean-Olivier Defraigne², Nicos Labropoulos⁶, Victor Legrand³, Jean-Baptiste Michel⁷, Christoph Nienaber⁸, Marc A. Radermecker², John A. Elefteriades⁹

¹Sigfried and Janet Weis Center for Research, Geisinger Clinic, Danville, Pennsylvania; ²Cardiovascular Surgery and ³Cardiology Departments, University Hospital of Liège, CHU, Liège, Belgium; ⁴Minneapolis Center for Epidemiological and Clinical Research, Department of Medicine (III-0), VA Medical Center, Minneapolis, Minnesota; ⁵Surgery Department, University of Otago, Dunedin, New Zealand; ⁶Department of Surgery, Stony Brook University Medical Center, Stony Brook, New York; ⁷INSERM U698, Paris, France; ⁸Heart Center Rostock, University of Rostock, Rostock, Germany; and ⁹Aortic Institute, Yale University School of Medicine, New Haven, Connecticut

Abstract

The current state of research and treatment on aortic diseases was discussed in the “3rd International Meeting on Aortic Diseases” (IMAD3) held on October 4–6, 2012, in Liège, Belgium. The 3-day meeting covered a wide range of topics related to thoracic aortic aneurysms and dissections, abdominal aortic aneurysms, and valvular diseases. It brought together clinicians and basic scientists and provided an excellent opportunity to discuss future collaborative research projects for genetic, genomics, and biomarker studies, as well as clinical trials. Although great progress has been made in the past few years, there are still a large number of unsolved questions about aortic diseases. Obtaining answers to the key questions will require innovative, interdisciplinary approaches that integrate information from epidemiological, genetic, molecular biology, and bioengineering studies on humans and animal models. It is more evident than ever that multicenter collaborations are needed to accomplish these goals.

Copyright © 2013 Science International Corp.

Key Words

Aortic aneurysm • Valvular disease • Epidemiology • Genetics • Surgical repair

Introduction

Aortic diseases, including aneurysms and dissections, and valvular diseases are a leading cause of morbidity worldwide. The current state of research and clinical practice on aortic diseases was discussed in a 3-day conference entitled “The 3rd International Meeting on Aortic Diseases (IMAD3)” held on October 4–6, 2012, in Liège, Belgium (Fig. 1; Table 1). The previous IMAD conferences held in 2008 and 2010, also in Liège, had attracted approximately 200 and 300 participants, respectively. The 2012 IMAD3 conference brought together ≈400 participants from 28 different countries and representing many different fields, from vascular surgery to genetics and bioengineering. The program was organized according to disease types, with day 1 devoted to thoracic aortic, day 2 to abdominal aortic, and day 3 to valvular diseases, with a total of >100 invited speakers (Table 1).

Here, we review some of the topics covered in the meeting. The conference brought up a number of opportunities for future collaborative research proj-






Figure 1. IMAD logo shown in the cover of the abstract booklet of IMAD3.

ects for genetic, genomics, and biomarker studies, as well as clinical trials.

Thoracic Aortic Diseases

The first day of IMAD3 was devoted to epidemiology, genetics, pathobiology, and different treatment

modalities of both rare syndromic forms and common nonsyndromic forms of thoracic aortic aneurysms (TAAs) and dissections (TAADs). Active research continues on rare syndromic forms of TAA and TAAD, revealing mutations responsive for the phenotypes and biological pathways important for the function and structural integrity of the thoracic aorta [1]. At

Table 1. Scientific Sessions and List of Speakers at IMAD3 in Liege, Belgium, October 4–6, 2012

Session Title and Moderators	Speaker	Affiliation
Opening session	Dimitris-Solon Georgopoulos	Agia Olga General Hospital, Greece
<i>Genetics, genomics and pathobiology of thoracic aortic diseases</i> Moderators: Eric Allaire and John A. Elefteriades	Bart Loeys Jean-Baptiste Michel Peter N. Robinson Julie De Backer Fransiska Malfait John A. Elefteriades Annette Baas Ayako Nagasawa Fabio Ramponi Julie Faugeron ^b Tiwari Kausal Adiguzel Zelal	University of Antwerp, Belgium INSERM, France Charite-Universitätmedizin, Germany University Hospital of Gent, Belgium University Hospital of Gent, Belgium Yale University, USA University Medical Center Utrecht, The Netherlands Yamaguchi University, Japan University of Sydney, Australia INSERM, France G. Pasquinucci Heart Hospital, Italy Genetic Engineering and Biotechnology Institute, Turkey
<i>Clinical management and treatment of thoracic aortic diseases</i> Moderators: Jean-Olivier Defraigne and Christoph Nienaber	Martin Czerny Luigi Lovato Christoph Nienaber Germano Melissano Thai An Nguyen Tilo Kölbel Ian Loftus John A. Elefteriades Thomas Bilfinger Carsten Bünger Stephan Kische Benjamin W. Starnes Frédéric Cochenne Natzi Sakalihasan Davide Patrini Jean-Marc Alsac Isabelle Bouckenooghe Bart Meuris ^a Janet Powell Rebecka Hultgren Frank A. Lederle	Inselspital, Switzerland University Hospital S. Orsola, Italy University of Rostock, Germany H. San Raffaele–Chirurgia Vascolare, Italy Cho Ray Hospital, Vietnam Universitätsklinikum, Hamburg-Eppendorf, Germany St. George's University of London, UK Yale University, USA Stony Brook Medical Center, USA Thorax-, Gefäß- und Transplantationschirurgie Universitätsklinik, Rostock, Germany University Hospital Rostock, Germany University of Washington, USA Centre Hospitalier Universitaire Henri Mondor, France University Hospital of Liège, Belgium Cliniche Gavazzeni-Bergamo, Italy Université René Descartes, France OLV Aalst, Belgium University Hospitals Leuven, Belgium Imperial College, UK Karolinska Institutet, Sweden Minneapolis VA Center for Epidemiology & Clinical Research, USA
<i>Epidemiology of AAA</i> Moderator: Frank Lederle	Paul Norman Soroush Sohrabi Jes Lindholt Kim Kargaard Bredahl Fredrik Lundgren Jordane Herail Rodolphe Durieux Jonathan Golledge Gerard Tromp Betti Giusti	University of Western Australia, Australia University of Leeds, UK Viborg Hospital, Denmark Rigshospital Copenhagen, Denmark University Hospital of Linköping, Sweden CHU Besançon, France University Hospital of Liège, Belgium James Cook University, Australia Geisinger Clinic, USA University of Florence, Italy
<i>Genetics and genomics of AAA</i> Moderator: Helena Kuivaniemi		

(table continues)

Table 1. (continued)

Session Title and Moderators	Speaker	Affiliation
<i>Pathophysiology and biomarkers of AAA</i> Moderators: Gillian Cockerill and Jes Lindholt	Jose Luis Martin Ventura Gillian Cockerill Joel Pincemail Koichi Yoshimura Joost A. Van Herwaarden Jesper Swedenborg Andrea Ascoli Marchetti Marc A Bailey Melina Vega de Céniga Osamu Yamashita José Monteiro	Autonoma University, Spain St. George's University of London, UK University Hospital of Liège, Belgium Yamaguchi University, Japan University Medical Center in Utrecht, The Netherlands Karolinska Institutet, Sweden University of Rome, Italy University of Leeds, UK Hospital de Galdakao-Usansolo, Spain Yamaguchi University, Japan University of Sao Paulo, Brasil
<i>Tips and tricks for better management in aortic surgery: team building</i> Moderators: Francine Blaffart and Filip De Somer	Francine Blaffart Filip De Somer Marc Schepens John Murkin Niels Rahe-Meyer Marc G Lagny	University Hospital of Liège, Belgium University Hospital Gent, Belgium AZ Sin. Jan Brugge, Belgium University of Western Ontario, Canada Hannover Medical School, Germany University Hospital of Liège, Belgium
<i>Creating standards for measuring AAA growth</i> Moderator: Eric Allaire	Henrik Sillesen Timothy Baxter Anders Wanhainen	Rigshospitalet, Denmark University of Nebraska, USA Uppsala University Hospital, Sweden
<i>Clinical management and treatment of distal arch, thoraco-abdominal and abdominal aortic aneurysms: Part I</i> Moderators: Nicos Labropoulos and Eric Verhoeven	Furuzan Numan Eric Verhoeven Michael Jacobs	Istanbul University, Turkey Klinikum Nürnberg Süd, Germany Maastricht University Medical Center, The Netherlands
<i>Clinical management and treatment of distal arch, thoraco-abdominal and abdominal aortic aneurysms: Part II</i> Moderators: Nicos Labropoulos and Hendrik Van Damme	Hence Verhagen Jason Lee Athanasios Giannoukas Nicos Labropoulos Frank Veith Frank Vermassen Gilberto Boselli Bertrand Saint-Lèbes V.A. Piccone Sebastien Deglise Roberto Gattuso Matthew Bown David Carey Daniel Swerdlow Anna Helgadóttir Gregory Jones Per Eriksson Grisha Pirianov Mohamed Salah Rebecka Hultgren Ewa Strauss Irene Hinterseher Viviane Kokje ^b Fernando Rodríguez-Pascual	Erasmus University Medical Center, The Netherlands Stanford University, USA University Hospital of Larissa, Greece Stony Brook University Medical Center, USA New York University, USA Universitair Ziekenhuis Gent, Belgium Reggio Emilia Public Hospital, Italy University Hospital of Toulouse, France Staten Island University Hospital, USA CHUV, Switzerland University Sapienza, Italy University of Leicester, UK Geisinger Clinic, USA University College London, UK deCODE Genetics, Iceland University of Otago, New Zealand Karolinska Institutet, Sweden St. George's University of London, UK UK SH-Campus Lübeck, Germany Karolinska Institutet, Sweden Polish Academy of Sciences, Poland Charite-Universitätmedizin, Germany Leiden University, The Netherlands Centro de Biología Molecular Severo Ochoa, Spain

(table continues)

Table 1. (continued)

Session Title and Moderators	Speaker	Affiliation
<i>Epidemiology, genetics and pathophysiology of valvular diseases</i> Moderators: Per Eriksson and Victor Legrand	Per Eriksson	Karolinska Institutet, Sweden
	Alessandro Della Corte	Second University of Naples, Italy
	Anders Franco-Cereceda	Karolinska Institutet, Sweden
	Jean Dumesnil	University Institute of Cardiology and Pneumology of Quebec, Canada
	Mohamed Salah	UK SH-Campus Lübeck, Germany
<i>Clinical management and treatment of valvular diseases</i> Moderators: Victor Legrand and Marc A. Radermecker	M. Buonocore	Second University of Naples, Italy
	V. D'Oria	Second University of Naples, Italy
	Laure Gillis	University Hospital of Liège, Belgium
	Luc Pierard	University Hospital of Liège, Belgium
	Carlo Di Mario	Royal Brompton Hospital, UK
<i>Perceval™ S. the truly sutureless valve: 5-year clinical results and first BeNeLux results</i> Moderator: Jean-Olivier Defraigne	Gebrine El Khoury	Clinique Universitaire de Saint-Luc, Belgium
	Vitalii Kravchenko	M. Amosov National Institute of Cardiovascular Surgery, Ukraine
	K.J. Griffin	University of Leeds, UK
	Victor Legrand	University Hospital of Liège, Belgium
	Inez Rodrigus	University Hospital of Antwerp, Belgium
<i>Recent advances and future directions of aortic diseases</i> Moderator: Frank Lederle	Bart Meuris	University Hospitals Leuven, Belgium
	Jean-Marc Marnette	CHR Namur, Belgium
	Suzanne Kats	University Hospital Maastricht AZM, The Netherlands
	Mattia Glauber	G. Pasquinucci Heart Hospital, Italy
	Frank Veith	New York University, USA
	Eric Allaire	Centre Hospitalier Universitaire Henri Mondor, France
	Jan Lindeman	Leiden University, The Netherlands
	Frank Lederle	Minneapolis VA Center for Epidemiology & Clinical Research, USA
	Natzi Sakalihasan	University Hospital of Liège, Belgium
	Christian Gasser	The Royal Institute of Technology, Sweden
	Tim McGloughlin	University of Limerick, Ireland
	Jes Lindholt	Viborg Hospital, Denmark
	Giampaolo Martufi	The Royal Institute of Technology, Sweden
	Alain Nchimi	University Hospital of Liège, Belgium
	Arend-Jan Nieuwland	Leiden University, The Netherlands
	Badri Vijaynagar ^a	University of Leicester, UK
	Nicoletta Charolidi	St. George's University of London, UK
	Laurence Rouet	MediSys, France

^aReceived the Raymond Limet Prize given to the 2 best posters/short communications on natural history and/or pathophysiology of abdominal aortic aneurysms.

^bReceived the Camillo Di Croce Prize given to the 2 best posters/short communications on familial and/or genetic aspects of aneurysms.

For details on the program, visit the conference Web site at <http://www.chuliege-ima.be/>.

least 15 distinct, rare diseases with vascular manifestations such as arterial tortuosity and dilatation or dissection of the aorta have been characterized in detail on the molecular level, and genetic defects have been identified [2–11]. The diseases include the arterial tortuosity syndrome, vascular type of the Ehlers-Danlos syndrome, cutis laxa (multiple subtypes), Loeys-Dietz syndrome (multiple subtypes), Marfan syndrome, multisystemic smooth muscle dysfunction

syndrome, type 5 of the Moyamoya disease, periventricular heterotopia, and Shprintzen-Goldberg cranio-synostosis syndrome. In most of these syndromes, the vascular manifestations occur in the aortic arch or the ascending or descending thoracic aorta, and it is rare to see aneurysms in the abdominal aorta. At least 13 different genes harbor mutations causing these 15 syndromic forms of aortic aneurysms and dissections [2–11]. Mutations in *ACTA2* (smooth muscle alpha ac-

tin) can lead to either the multisystemic smooth muscle dysfunction syndrome or the type 5 subtype of the Moyamoya disease [12]. Similarly, mutations in the *TGFBR1* and *TGFBR2* (transforming growth factor, beta receptor) genes can lead to phenotypic heterogeneity and classification of the patient into different subtypes of the Loeys-Dietz syndrome [13]. Because the number of patients studied for most of these conditions is small, it is difficult to make generalizations about genotype-phenotype correlations. What can be concluded, however, is that many of the genes encoding members of two biological pathways, the transforming growth factor- β (TGF β)-signaling pathway and the contractile apparatus of the smooth muscle cell, are mutated in these patients. The proteins of the extracellular matrix constitute the third important category of proteins defective in some of the patients. Future research efforts will include development and refinement of animal models for these conditions and the testing of different pharmaceutical compounds as medical treatment options [1,4,6].

Dr. Julie De Backer presented a comprehensive review of the treatment of Marfan syndrome. β -Blockers, although the standard of therapy, are largely unproven in effectiveness. Many promising clinical trials of TGF β antagonism by losartan (an angiotensin receptor blocker) will come to fruition within the next few years. New information on molecular mechanisms of aortic disease in Marfan syndrome could lead to new treatment options in the future. For example, experiments performed in a mouse model in Dr. Peter Robinson's laboratory showed that treatment with the BA4 antibody neutralized fibrillin fragments and ameliorated aortic pathology [14].

The myocardium appears to be adversely affected, in both its systolic and diastolic function, in patients with Marfan syndrome. Fibrillin-1 is expressed in myocardium [15].

Vascular Ehlers-Danlos syndrome continues to elude preventative therapy, with most patients presenting with catastrophic arterial hemorrhage, usually in the abdomen or head or neck region. Empirical therapy with the particular β -blocker celiprolol can be considered [16]. A new animal model developed by Dr. Fransiska Malfait will enable advances in this syndrome.

The Yale group is accumulating evidence that patients with aortic root aneurysm are protected from systemic arteriosclerosis. Comparative studies found

lower total-body arterial calcium (a late arteriosclerotic indicator) and lower carotid intima-media thickness (an early arteriosclerotic indicator) [17,18]. These clinical observations are consistent with the earlier findings by Grainger that indicated that TGF β has anti-atherogenic properties [19].

The quest for clinically useful biomarkers of aortic disease has largely run fallow [20]. Although D-dimer is 100% sensitive for aortic dissection, it rises after dissection has occurred and therefore has no utility in prediction. A Yale "RNA signature" holds promise to provide a general diagnostic test and a real-time indicator ("virtual biopsy") of aortic molecular biology [21].

In the session on how to improve management of aortic surgery, the importance of achieving optimal brain protection to avoid ischemia by use of systemic hypothermia was discussed by Dr. Filip De Somer. A surgical approach to visceral, spinal cord, and cerebral protection has been developed by Dr. Marc Schepens. The spinal cord protection, achieved by use of a left-left bypass, permissive hypothermia, evoked potential monitoring, reimplantation of critical arteries, and cerebrospinal fluid drainage, can greatly reduce the risk of neurological deficits after thoracoabdominal aortic surgery with or without bypass. Deep hypothermic circulatory arrest with or without antegrade selective cerebral perfusion can be useful for cerebral protection during arch surgery.

Transcranial Doppler and cerebral oximetry are technologies helpful in avoiding intraoperative desaturation. Dr. John Murkin described an algorithm for intraoperative use of cerebral near-infrared spectroscopy (NIRS) and low cerebral saturation. Dr. Niels Rahe-Meyer discussed coagulation management during and after complex cardiovascular surgery. The amount of blood loss during the surgery and preoperative fibrinogen levels were correlated. Fibrinogen infusion successfully reduced the rate of bleeding and allogeneic blood transfusion in the postoperative period. Despite recent improvements in prevention, medical treatment [22], and endovascular aortic repair, invasive surgery associated with cardiopulmonary bypass remains the best option for treatment of some patients. Dr. Marc Lagny discussed cardiopulmonary bypass procedures and aortic surgery. Arterial cannulation requires special attention because of the possibility of local dissection, malperfusion, or embolic events. Strategies to achieve good cerebral protection include hypothermia with or without selective cere-

bral perfusion [23,24]. Perfusion plays an important role in blood management [25] during the potentially hemorrhagic surgery.

Pathophysiology of TAADs is Complex

The TGF β signaling pathway plays a critical role in TAAs [6]. Activation of the TGF β /SMAD2 pathway is characterized by accumulation of activated phosphorylated SMAD2 (pSMAD2) [26]. The amounts of TGF β 1 protein retained within and released by aneurysmal tissue were greater than for control aortic tissue, contrasting with unchanged TGF β 1 mRNA levels. Increased stored TGF β 1, TGF β binding protein-1 (LTBP1) protein and mRNA, phosphorylated SMAD2, and SMAD2 mRNA levels were detected in the ascending aortic wall from all types of TAAs. In addition, a complex dysregulation of SMAD2 signaling, independent of TGF β 1, was observed in TAA-derived cultured vascular smooth muscle cells. The cell specificity of this overexpression strongly implicated epigenetic control of SMAD2 expression [27], and an increase in H3K9/14 acetylation and H3K4 methylation was detected by chromatin immunoprecipitation in a cell-specific and transcription start site-specific manner.

Another interesting pathophysiological question studied by Dr. Jean-Baptiste Michel's laboratory is whether aneurysms in the thoracic ascending aorta induce platelet activation and thrombin formation [28,29]. The amounts of P-selectin and platelet-bound fibrinogen were increased, demonstrating platelet activation. Transparietal concentration and activation (thrombin formation) of prothrombin was enhanced in TAA wall compared with healthy aortas [29]. Thrombin/antithrombin complex formation was also increased through the TAA wall. Moreover, prothrombin/thrombin was retained in areas of mucoid degeneration.

Because activation of the pericellular fibrinolytic system leads to degradation of adhesion proteins, activation of matrix metalloproteinases, loss of vascular smooth muscle cells [30], and an increase in the bioavailability of TGF β , the ability of the plasminergic system to be activated in TAAs was also investigated [31]. Immunohistochemical staining showed accumulation of tissue (tPA) and urokinase (uPA) plasminogen activators and plasmin in TAAs, associated with residual vascular smooth muscle cells. Plasminogen was present on the surface of smooth muscle cells and inside cytoplasmic vesicles, but plasminogen mRNA

was undetectable in the TAA medial layer, which suggests that plasminogen originates from plasma. Fibronectin-related material was detected immunohistochemically in dense clumps around smooth muscle cells and colocalized with LTBP1.

Diseases of the Abdominal Aorta

The second day of IMAD3 was devoted to epidemiology, genetics, pathobiology, and different treatment modalities of abdominal aortic aneurysms (AAAs).

Decreasing Trends in AAA Prevalence and Mortality

In the past few years, studies from around the world have described a marked decline in AAA prevalence and mortality. Smoking is perhaps the strongest predictor of AAA, and the temporal pattern of the rise and fall of smoking rates roughly parallels the changes in AAA mortality. To gain insight into this and other explanatory factors, the Charing Cross group combined the strength of risk factors as judged from multivariate regression models with the change in their prevalence over time to try to estimate the contribution of each to the decline in AAA mortality [32]. Their modeling suggested that in addition to smoking, increased use of elective repair and of statins and antihypertensive drugs all likely contributed to the decline in AAA mortality.

Unlike cerebral and thoracic aneurysms, AAAs are much less common in women than in men. The reasons for this difference have been difficult to pin down. A protective effect of female sex hormones has been postulated and demonstrated in animal models, but studies of hormone use and biomarkers in humans have been inconclusive [33]. Also unexplained are the apparently higher rupture rate of AAAs in women and the more frequent finding of concurrent aneurysms in the thoracic aorta [34]. With few answers available, gender differences remain an important area of AAA research.

Another topic discussed at IMAD3 involved factors that contribute to AAA enlargement. Large data sets have been examined looking especially for evidence of reduced enlargement rate associated with use of common drugs such as statins, angiotensin-converting enzyme (ACE) inhibitors, and calcium blockers. These have been difficult to identify, and one reason

may be what has been termed *index event bias* [35]. This describes a phenomenon whereby risk factors that contribute to a patient being diagnosed with a disease continue to operate in that individual but do not stand out as being predictive of progression compared with other risk factors that continue to operate in other diagnosed individuals.

In addition to their intended purpose of identifying AAAs, data from large screening studies have allowed assessment of the relationship of aortic diameter to various outcomes. Several studies have found that an aortic diameter larger than normal but still well below the range of an AAA may be predictive of cardiovascular mortality and of peripheral artery disease [36]. Further research is needed to determine whether individuals with above-normal aortic diameters might benefit from more intensive risk identification and modification.

AAA is a Complex Disease with Multiple Genetic Risk Factors

AAA has a significant genetic component, with twin studies reporting heritability of $\approx 70\%$ [37]. The pattern of inheritance appears to be autosomal, although evidence for both recessive and dominant models has been suggested [38].

Although numerous candidate gene associations have been published [38,39], only three large-scale genome-wide association studies (GWAS) have been reported for AAA [40–42]. To date, only four genetic associations, the *CDKN2BAS1* locus (9p21) [43], *DAB2IP* (9q33) [42], *LRP1* (12q13) [41], and *IL6R* [44], have reached genome-wide significance ($P < 10^{-8}$) and have been replicated in different populations. Although some of these markers (*CDKN2BAS1* and *DAB2IP*) appear to have concurrent associations with other forms of arterial disease, *LRP1* may represent an AAA-specific association. Another highly significant ($P = 0.00006$) association was found recently with AAA and single-nucleotide polymorphisms (SNPs) in the apolipoprotein(a) (*LPA*) gene [45].

Future genetic discovery in AAAs is likely to be made via two complementary strategies. First, meta-analysis of GWAS data sets will significantly improve the statistical power to detect disease-associated SNPs. The largest AAA GWAS reported to date included 1866 cases [41]; however, meta-analysis of all currently existing GWAS, from the United Kingdom, the Netherlands, Iceland, New Zealand, and the United

States, would combine $>5,000$ cases and $>60,000$ controls. This approach has been shown to be an effective discovery tool in other cardiovascular phenotypes, such as coronary artery disease (CAD) [46] and dyslipidemia [47]. A strategy to combine all published and unpublished AAA GWAS data and perform a meta-analysis with follow-up replication was discussed and endorsed at IMAD3.

The second alternative SNP discovery strategy is to utilize prior knowledge of biological associations, such as CAD and dyslipidemia, to facilitate analysis of GWAS data sets [48]. For example, because >100 loci have been convincingly associated with CAD or dyslipidemia in large-scale meta-analyses, these regions may also be risk loci for AAA, as is the case for the chr9p21 *CDKN2BAS1* locus. Investigation of AAA GWAS data sets by use of a “focused” set of SNPs with prior knowledge significantly reduces the multiple testing correction requirements typically associated with whole-genome analysis.

Regardless of the approach to genetic discoveries, it is clear that there is potential overlap between genetic risk for concurrent vascular diseases, such as AAA, CAD, and peripheral artery disease, and associated risk factors, such as dyslipidemia and smoking [49]. It will therefore be important that future genetic studies be able to statistically model these interactions. The eMERGE Network, organized by the National Human Genome Research Institute, is one example of a study group that has recognized the need for integrated genetic, demographic, and clinical data analysis [50]. Such studies will be vital if genetic risk is to be successfully integrated into the demographic and clinically based risk models that are currently in clinical practice.

Finally, although these approaches are capable of identifying independent genetic risk factors, the biological mechanisms underpinning these associations are not always clear. Functional studies linking SNP genotypes with tissue-specific gene expression profiles by Folkersen and colleagues [51] demonstrated that approximately half of the 166 cardiovascular risk SNPs investigated influenced expression of genes in close proximity. A smaller number of SNPs, however, appeared to influence genes that were not in the immediate vicinity of the risk SNP, nor were these variants in linkage disequilibrium with another SNP near the gene. In addition, SNP-associated gene effects were tissue specific, and tissue specificity was

phenotype dependent (for example, lipid metabolism SNP-gene effects were predominantly liver-specific). This suggests that SNP-gene expression mechanisms are complex, and considerable caution is needed when interpreting possible pathological mechanisms underpinning SNP-phenotype associations.

Inflammation and Oxidative Stress Play Key Roles in AAA Pathophysiology

On the basis of histological and molecular studies, the aortic wall tissue from human AAAs large enough to be repaired shows extensive inflammation, vascular smooth muscle cell loss, and extracellular matrix degradation, as well as increased amounts of matrix metalloproteinases and oxidative stress [1,52–54]. These features have also been key findings in recent unbiased genomic and proteomic studies, which confirms their relevance to the disease pathophysiology [1,52–55].

The search for biomarkers detectable in human serum or plasma that could help to identify patients with AAAs, monitor the growth of existing AAAs, or predict the rupture of AAAs is of critical importance [56–61]. Some of the recently identified promising AAA biomarkers are catalase (CAT, an enzyme that converts the reactive oxygen species hydrogen peroxide to water and oxygen, thereby mitigating the toxic effects of hydrogen peroxide) [58], peroxiredoxin 1 (PRDX1, also known as the natural killer cell-enhancing factor A) [57], and lipocalin 2 (LCN2, also known as neutrophil gelatinase-associated lipocalin, NGAL, a marker of neutrophil activation) [59].

In a small study of 63 AAA patients, statin treatment reduced aortic wall inflammation by decreasing the levels of nuclear factor- κ B, interleukin 6 (IL6), and chemokine (C-C motif) ligand 2 (CCL2, also known as the monocyte chemoattractant protein 1, MCP1), as well as proteases cathepsin K and S [62]. These effects appeared to be independent of lipid-lowering effects of statins. In contrast, no effect was seen on AAA growth in a separate study of 142 AAA patients [62].

Studies on aortic aneurysms in animal models are also crucial in identifying the early molecular mechanisms that lead to AAA development and growth and in testing ways to prevent or delay the growth of AAAs [63–65]. In one study performed with an AAA mouse model, lysyl oxidase, an enzyme needed for crosslinking of elastin and collagen molecules, was shown to

reduce CCL2 and prevent macrophage infiltration and AAA progression [63]. In another mouse study discussed at IMAD3, increasing plasma high-density lipoproteins (HDLs) inhibited aortic aneurysm formation via reduced ERK1/2 activation [65]. In a third mouse study, administration of rosiglitazone, an agonist of the nuclear peroxisome proliferator-activated receptors, to mice induced to have aortic aneurysms led to a marked reduction of both aneurysm rupture and development. Rosiglitazone appeared to modulate inflammatory processes by blocking TLR4/JNK (toll-like receptor/c-Jun N-terminal kinase) signaling [64].

Different regions of the human aorta differ in their embryological origins, structure of the aortic wall, and disease susceptibility. Gene expression studies have also shown differences between the thoracic and abdominal aorta. For example, the expression of many homeodomain-containing genes, the so-called HOX genes, demonstrates spatial expression patterns along the length of the aorta, and these genes have decreased expression in human AAA compared with nonaneurysmal aorta [66].

Differences in expression levels of a large number of different genes have been identified between human AAA and nonaneurysmal control aortic samples [1]. The next step is to understand how the expression of these genes is regulated and how it could be modified medically to slow the growth rate of AAAs. These studies have led to the discovery of transcription factors and microRNAs that control the expression of genes in the human aorta [67,68].

Update on Treatment Options for AAA

Patients with small AAAs are being followed up based on the diameter of the AAA and may be treated medically, including by risk factor modification, such as antihypertensive and lipid-lowering drugs, as well as antibiotics and β -blockers. A recent meta-analysis of 4647 patients showed a significant reduction in AAA growth rates in patients taking statins compared with those who did not [69], but other meta-analyses failed to show a growth rate reduction [70,71].

Another meta-analysis on the effects of antibiotics and β -blockers on AAA growth showed that roxithromycin provided a small but significant protective effect and β -blockers showed a very small protective effect on AAA expansion [72]. ACE inhibitors suppress the development of elastase-induced AAA in mice.

Patients taking ACE inhibitors before hospital admission were less likely to present with a ruptured aneurysm than those who did not [73]. Anti-inflammatory agents, inhibitors of mast cell degranulation to reduce aortic wall expansion, and JNK inhibitors are some other potential pharmacological agents that have so far been used only in animal models [74].

The advantages of endovascular aneurysm repair (EVAR) over open surgical repair (OSR) include significantly lower periprocedural stress for the patient, which results in early mobilization, a limited need for a stay in the intensive care unit, a shorter overall hospital stay, and significantly lower early complication and mortality rates [75]. These early benefits disappear over time. Approximately 20% of all EVAR patients will require reintervention during follow-up, and 1% will experience aneurysm rupture after EVAR. Reports on more recent patient cohorts indicate a gradual improvement in these figures, mainly attributed to better preoperative planning and device design [76]. Endoleaks, aortic and endograft remodeling, and the potential for aneurysm rupture after elective repair make long-term surveillance necessary. Elective EVAR in patients aged ≥ 80 years yields significantly lower immediate postoperative mortality and morbidity than OSR and should be considered the treatment of choice in these patients. Long-term survival is certainly lower, which reflects the more extensive comorbidities in this patient subgroup [77]. Anatomic constraints, specifically adequate access vessels, sufficient proximal and distal landing zones, and angulation, along with the need for long-term surveillance, are the main EVAR limitations. As endografts continue to be modified, many of the initial difficulties may be overcome, leading to a more widespread adoption of this treatment modality.

Reports from centers performing large numbers of OSRs demonstrated low perioperative morbidity and mortality, but population-based studies showed higher mortality of up to 8% [78]. Patients with an acceptable risk profile, despite an increased early mortality and a longer recovery period than with EVAR, have similar mid- and long-term outcomes and perhaps better long-term quality of life. Currently, anatomic unsuitability for EVAR is one of the main indications for OSR, and therefore, OSR is more common in female patients. Perioperative complications include cardiac ischemic events, arrhythmias, hemorrhage, renal and respiratory failure, colonic ischemia,

and distal embolization. Long-term complications are uncommon and include graft infection, erosion to nearby structures, abdominal wall hernias, and anastomotic disruption.

Valvular Diseases

Bicuspid aortic valve (BAV) is the most prevalent inherited cardiac malformation [79] and accounts for 30%–50% of all adult aortic valve pathologies that undergo operation in Western countries [80]. The association between BAV and diseases of the ascending aorta was emphasized during IMAD3, although the nature and the extent of the relationship remain unclear [81]. Over the past 15 years, the hypothesis that the “intrinsic pathology” of the ascending aorta was the main determinant for aneurysm development and aortic complications has prevailed. This intrinsic/genetic pathology hypothesis was supported by the recognition of the role of neural crest cells in the development of both aortic valve and ascending aorta pulmonary trunk [82], as well as by specific features of the dilated aorta with BAV compared with tricuspid valves [83–85].

The alternative hypothesis, supported by recent hemodynamic and flow-imaging studies, emphasizes the role of abnormal mechanical stress on the aortic wall in BAV [86]. The abnormal parietal stress in specific regions of the ascending aorta is related to jet asymmetry, which in itself is conditioned by the opening and therefore the morphology of the BAV (position of the raphe, i.e., area of fusion between the two incompletely developed cusps and corresponding hypoplastic in the leaflet triangle) [87].

The stress-induced aortopathy hypothesis is also supported by many clinical observations reporting the relatively good prognosis of patients with mild to moderate aortic dilatation after isolated aortic valve replacement [88,89]. The pendulum therefore swings from an intrinsic degenerative aortopathy deserving special prophylactic management, such as in Marfan syndrome, toward a more mechanistic, stress-driven disease in which size remains the best predictor of complications. This relative shift of paradigm has influenced the guidelines for the valve and aortic management in BAV. There is a trend toward recommending prophylactic replacement of

the ascending aorta, if >45–50 mm, except if the aneurysm is rapidly progressing or in case of a strong family history of dissection or rupture or with planned pregnancy. Guidelines of the American College of Cardiology, American Heart Association, and the European Society of Cardiology recommend elective repair in symptomatic patients with dysfunctional BAV [90,91]. At IMAD3, the Saint-Luc group from Brussels reported on 475 patients undergoing aortic valve repair for aortic insufficiency or aortic aneurysm with outstanding outcomes for the reimplantation technique with or without leaflet repair, the only obstacle to a conservative surgery being the intrinsic quality of the leaflet [92].

Benefits of medical therapy on aortic valve disease are limited. According to European Society of Cardiology guidelines, vasodilators and inotropic agents can be used to improve the condition of severe heart failure patients before proceeding with aortic valve surgery. In individuals with chronic severe aortic regurgitation and heart failure, vasodilators (ACE inhibitors and angiotensin-receptor blockers, ARB) are useful in hypertensive patients when surgery is contraindicated or left ventricular dysfunction persists postoperatively. Benefits of these agents or the dihydropyridine calcium channel blockers in asymptomatic patients without hypertension in order to delay surgery are unknown. In patients with Marfan syndrome, β -blockers may slow aortic root dilatation and reduce the risk of aortic complications and should be considered before and after surgery. Preliminary findings suggest that selective ARBs promote preservation of elastin fibers in the aortic wall, but their clinical benefit remains to be proven by ongoing trials [90].

Transcatheter aortic valve implantation was discussed in the presence of severe aortic stenosis. Results from the subclavian approach are encouraging and may (with the 18F CoreValve ReValving System) avoid the need for transapical approach. From the experience in octogenarians reported by Dr. Inez Rodriguez and the discussion of “difficult” clinical cases by Dr. Victor Legrand, a consensus emerged among the participants that the transcatheter aortic valve implantation procedure should be reserved for patients with definite contraindication to surgery or high-risk surgery, provided an improvement in the quality of life can be obtained.

Recent Advances and Future Directions of Aortic Diseases

The last session of the IMAD3 was devoted to presentations discussing recent and future developments related to aortic diseases, such as whether outcomes differ between EVAR and open repair for AAA and whether it is possible to tell which AAA is going to rupture and which one is more stable either by positron emission tomography (PET) imaging studies or by use of predictive modeling of wall stress.

In the OVER trial (Open Versus Endovascular Repair Trial for Abdominal Aortic Aneurysms), a 9-year VA Cooperative study, endovascular and open repair resulted in similar long-term survival [93]. The perioperative survival advantage of endovascular repair was significant for 3 years, but the survival curves were the same from 5 years onward. Six ruptures occurred during 4,576 patient-years of follow-up (1.3/1,000 patient-years), less than one third the rate seen in EVAR-1 (25 ruptures during 5309 patient-years of follow-up; 4.7/1,000 patient-years), but as in EVAR-1, all were in the endovascular group, which remains a cause for concern. Endovascular repair resulted in better long-term survival in patients younger than 70 years but tended to be worse in older patients, for whom it had been most hoped a benefit could be shown [93].

Conventional imaging tools give anatomic and morphological information about aneurysms, but the key question is how to identify aneurysms with the highest activity of inflammation and oxidative stress. Recently developed imaging techniques such as PET provide molecular and cellular evaluation of atherothrombosis in the arterial wall [54,94–96]. PET studies are performed with fluorodeoxyglucose (FDG) F 18, a glucose analog, which reflects glucose uptake and metabolism in the cell. Once inside the cells, FDG is phosphorylated to FDG-6-phosphate, which is not a substrate for the enzymes of the glycolytic chain. Several PET studies have investigated its usefulness to monitor the development and rupture risk of AAAs. An association between ^{18}F -FDG uptake by the aneurysm wall and rapid expansion of the aneurysm was found in some cases [95–99]. A correlation between the increased FDG uptake and high macrophage activity in symptomatic AAAs has also been reported [97], but no correlation between maximum standard uptake value and maximum cross-sectional infrarenal AAA

diameter was found [98]. In their recent study of >270 patients (unpublished data presented during IMAD3), Sakalihasan et al confirmed an association between ^{18}F -FDG uptake by the aneurysm wall and rupture of the aneurysm in seven cases, four of which were <55 mm in diameter. None of the patients without ^{18}F -FDG uptake developed any of the clinical signs or symptoms of the PET-positive patients.

Although previous biomechanics studies using finite element analysis demonstrated a strong correlation between high wall stress and rupture, the influence of local variation, such as presence of thrombus and asymmetry of AAA, needs to be better understood [100–102]. The initial change in an aneurysm is structural and results from a degenerative process in the vascular wall. As the morphology changes, the blood flow pattern changes, with consequential modification of fluid stresses and their interaction with the mechanical stresses within the arterial wall [96]. At IMAD3, the possible correlation between the growth rate of an AAA and biomechanical rupture risk factor indices such as peak wall stress and peak wall rupture risk were also discussed. The biomechanical AAA rupture risk assessment integrates information on size, shape, sex, wall weakening associated with the intraluminal thrombus, family history, and elevated blood pressure. The rupture risk equivalent diameter expresses this information through the diameter of the “average” AAA with the same risk of rupture, i.e., having the same peak wall rupture risk. Consequently, the rupture risk equivalent diameter reflects an individualized biomechanical assessment of the diameter-based information collected from clinical studies. A study using three-dimensional aneurysm models based on computerized tomographic angiography concluded that multiple centerline-based diameter measurements could help clinicians decide when to operate on AAAs [103].

Concluding Remarks

In this report, we have summarized recent discoveries concerning epidemiology, genetics, pathophysiology, and treatments of diseases that affect the tho-

racic and abdominal aorta, as well as the aortic valve. Considerable progress has been made recently, but there is clearly much work to be undertaken, for example, in identifying novel biomarkers and understanding the biological mechanisms of the genetic associations. It is encouraging that highly collaborative multinational approaches have been adopted that are likely to yield further substantial advances in the near future.

The codirectors of this meeting witnessed with delight the diversity of the meeting participants, who came from 28 different countries, and were particularly pleased to see the large number of junior investigators presenting. Four highly competitive travel awards in honor of the late professor Raymond Limet and Camillo Di Croce (Table 1) were given to junior investigators. The tradition of Liège meetings will continue, and planning for the fourth *International Meeting on Aortic Diseases* (IMAD4) is already in progress. It will take place in Liège, Belgium, in 2014 (for details, please visit the conference website at <http://www.chuliege-ima.be/>).

Acknowledgments

IMAD3 was made possible by generous support from Sorin Group; Johnson & Johnson; Edwards Lifesciences; Hospithera; Maquet Getinge Group; St. Jude Medical; Lemaitre Vascular; Cardoz; Cook Medical; Baxter; B. Braun; Endologix; Ethicon; Eurox; Medcor; Vitalitec; Medtronic; Aneurysmal Pathology Foundation; Fighting Aneurysmal Disease; the Department of Cardiovascular and Thoracic Surgery, CHU Liège; and the Province of Liège. The Divine [id] agency from France (www.divine-id.com) and personnel, in particular Genevieve Peters, at the Department of Cardiovascular and Thoracic Surgery, CHU Liège, are gratefully acknowledged for taking care of the practical matters of the conference. The authors of this report were directors of IMAD3. They thank their colleagues for their help in summarizing the discussions.

Comment on this Article or Ask a Question

References

- Kuivaniemi H, Tromp G, Carey DJ, Elmore JR. The molecular biology and genetics of aneurysms. In: Homeister JW, Willis MS, eds. *Molecular and Translational Vascular Medicine*. New York, NY: Springer Science+Business Media. 2012;3–33.
- De Paepe A, Malfait F. The Ehlers-Danlos syndrome, a disorder with many faces. *Clin Genet*. 2012;82:1–11. 10.1111/j.1399–0004.2012.01858.x
- Doyle AJ, Doyle JJ, Bessling SL, Maragh S, Lindsay ME, Schepers D, et al. Mutations in the TGF-beta repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. *Nat Genet*. 2012;44:1249–1254. 10.1038/ng.2421
- Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, et al. Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. *Science*. 2011;332:358–361. 10.1126/science.1192149
- Kaplanayil M, Nampoothiri S, Kannan R, Renard M, Coucke P, Malfait F, et al. Characterization of a distinct lethal arteriopathy syndrome in twenty-two infants associated with an identical, novel mutation in FBLN4 gene, confirms fibulin-4 as a critical determinant of human vascular elastogenesis. *Orphanet J Rare Dis*. 2012;7:61. 10.1186/1750–1172-7–61
- Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. *Nature*. 2011;473:308–316. 10.1038/nature10145
- Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, et al. Loss-of-function mutations in TGFβ2 cause a syndromic presentation of thoracic aortic aneurysm. *Nat Genet*. 2012;44:922–927. 10.1038/ng.2349
- Moberg K, De Nobele S, Devos D, Goetghebuer E, Segers P, Trachet B, et al. The Ghent Marfan Trial: A randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with beta-blockers. *Int J Cardiol*. 2012;157:354–358. 10.1016/j.ijcard.2010.12.070
- van de Laar IM, van der Linde D, Oei EH, Bos PK, Bessems JH, Bierma-Zeinstra SM, et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. *J Med Genet*. 2012;49:47–57. 10.1136/jmedgenet-2011–100382
- van der Linde D, van de Laar IM, Bertoli-Avella AM, Oldenburg RA, Bekkers JA, Mattace-Raso FU, et al. Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. *J Am Coll Cardiol*. 2012;60:397–403. 10.1016/j.jacc.2011.12.052
- Carmignac V, Thevenon J, Ades L, Callewaert B, Julia S, Thauvin-Robinet C, et al. In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome. *Am J Hum Genet*. 2012;91:950–957. 10.1016/j.ajhg.2012.10.002
- Milewicz DM, Østergaard JR, Ala-Kokko LM, Khan N, Grange DK, Mendoza-Londono R, et al. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. *Am J Med Genet A*. 2010;152A:2437–2443. 10.1002/ajmg.a.33657
- Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, et al. Genetic basis of thoracic aortic aneurysms and dissections: Focus on smooth muscle cell contractile dysfunction. *Annu Rev Genomics Hum Genet*. 2008;9:283–302. 10.1146/annurev.genom.8.080706.092303
- Guo G, Munoz-Garcia B, Ott CE, Grunhagen J, Mousa SA, Pletschacher A, et al. Antagonism of GxxPG fragments ameliorates manifestations of aortic disease in Marfan syndrome mice. *Hum Mol Genet*. 2012;22:433–443.
- De Backer JF, Devos D, Segers P, Matthys D, Francois K, Gillebert TC, et al. Primary impairment of left ventricular function in Marfan syndrome. *Int J Cardiol*. 2006;112:353–358. 10.1016/j.ijcard.2005.10.010
- Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. *Lancet*. 2010;376:1476–1484. 10.1016/S0140–6736(10)60960–9
- Achneck H, Modi B, Shaw C, Rizzo J, Albornoz G, Fusco D, Elefteriades JA. Ascending thoracic aneurysms are associated with decreased systemic atherosclerosis. *Chest*. 2005;128:1580–1586. 10.1378/chest.128.3.1580
- Hung A, Zafar M, Mukherjee S, Tranquilli M, Scoult LM, Elefteriades JA. Carotid intima-media thickness provides evidence that ascending aortic aneurysm protects against systemic atherosclerosis. *Cardiology*. 2012;123:71–77. 10.1159/000341234
- Grainger DJ. TGF-beta and atherosclerosis in man. *Cardiovasc Res*. 2007;74:213–222. 10.1016/j.cardiores.2007.02.022
- Trimarchi S, Sangiorgi G, Sang X, Rampoldi V, Suzuki T, Eagle KA, Elefteriades JA. In search of blood tests for thoracic aortic diseases. *Ann Thorac Surg*. 2010;90:1735–1742. 10.1016/j.athoracsurg.2010.04.111
- Wang Y, Barbacioru CC, Shiffman D, Balasubramanian S, Iakoubova O, Tranquilli M, et al. Gene expression signature in peripheral blood detects thoracic aortic aneurysm. *PLoS One*. 2007;2:e1050. 10.1371/journal.pone.0001050
- Bonser RS, Ranasinghe AM, Loubani M, Evans JD, Thalji NM, Bachet JE, et al. Evidence, lack of evidence, controversy, and debate in the provision and performance of the surgery of acute type A aortic dissection. *J Am Coll Cardiol*. 2011;58:2455–2474. 10.1016/j.jacc.2011.06.067
- Elefteriades JA. What is the best method for brain protection in surgery of the aortic arch? *Straight DHCA. Cardiol Clin*. 2010;28:381–387. 10.1016/j.ccl.2010.02.004
- Shann KG, Likosky DS, Murkin JM, Baker RA, Baribeau YR, DeFoe GR, et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. *J Thorac Cardiovasc Surg*. 2006;132:283–290. 10.1016/j.jtcvs.2006.03.027
- Rahe-Meyer N. Fibrinogen concentrate in the treatment of severe bleeding after aortic aneurysm graft surgery. *Thromb Resm*. 2011;128(suppl 1):S17–S19.
- Gomez D, Al Haj Zen A, Borges LF, Philippe M, Gutierrez PS, Jondeau G, et al. Syndromic and non-syndromic aneurysms of the human ascending aorta share activation of the Smad2 pathway. *J Pathol*. 2009;218:131–142. 10.1002/path.2516
- Gomez D, Coyet A, Ollivier V, Jeunemaitre X, Jondeau G, Michel JB, Vranckx R. Epigenetic control of vascular smooth muscle cells in Marfan and non-Marfan thoracic aortic aneurysms. *Cardiovasc Res*. 2011;89:446–456. 10.1093/cvr/cvq291
- Jondeau G, Michel JB, Boileau C. The translational science of Marfan syndrome. *Heart*. 2011;97:1206–1214. 10.1136/hrt.2010.212100
- Michel JB, Thauinat O, Houard X, Meilhac O, Caligiuri G, Nicoletti A. Topological determinants and consequences of adventitial responses to arterial wall injury. *Arterioscler Thromb Vasc Biol*. 2007;27:1259–1268. 10.1161/ATVBAHA.106.137851
- Meilhac O, Ho-Tin-Noe B, Houard X, Philippe M, Michel JB, Angles-Cano E. Pericellular plasmin induces smooth muscle cell anoikis. *FASEB J*. 2003;17:1301–1303.
- Borges LF, Gomez D, Quintana M, Touat Z, Jondeau G, Leclercq A, et al. Fibrinolytic activity is associated with presence of cystic medial degeneration in aneurysms of the ascending aorta. *Histopathology*. 2010;57:917–932. 10.1111/j.1365–2559.2010.03719.x
- Anjum A, von Allmen R, Greenhalgh R, Powell JT. Explaining the decrease in mortality from abdominal aortic aneurysm rup-

- ture. *Br J Surg*. 2012;99:637–645. 10.1002/bjs.8698
33. Villard C, Wagsater D, Swedenborg J, Eriksson P, Hultgren R. Biomarkers for abdominal aortic aneurysms from a sex perspective. *Gend Med*. 2012;9:259–266.e252.
 34. Hultgren R, Larsson E, Wahlgren CM, Swedenborg J. Female and elderly abdominal aortic aneurysm patients more commonly have concurrent thoracic aortic aneurysm. *Ann Vasc Surg*. 2012;26:918–923. 10.1016/j.avsg.2012.01.023
 35. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. *JAMA*. 2011;305:822–823. 10.1001/jama.2011.163
 36. Norman PE, Muller J, Golledge J. The cardiovascular and prognostic significance of the infrarenal aortic diameter. *J Vasc Surg*. 2011;54:1817–1820. 10.1016/j.jvs.2011.07.048
 37. Wahlgren CM, Larsson E, Magnusson PK, Hultgren R, Swedenborg J. Genetic and environmental contributions to abdominal aortic aneurysm development in a twin population. *J Vasc Surg*. 2010;51:3–7. 10.1016/j.jvs.2009.08.036
 38. Sandford RM, Bown MJ, London NJ, Sayers RD. The genetic basis of abdominal aortic aneurysms: A review. *Eur J Vasc Endovasc Surg*. 2007;33:381–390. 10.1016/j.ejvs.2006.10.025
 39. Hinterseher I, Tromp G, Kuivaniemi H. Genes and abdominal aortic aneurysm. *Ann Vasc Surg*. 2011;25:388–412. 10.1016/j.avsg.2010.09.004
 40. Elmore JR, Obmann MA, Kuivaniemi H, Tromp G, Gerhard GS, Franklin DP, et al. Identification of a genetic variant associated with abdominal aortic aneurysms on chromosome 3p12.3 by genome wide association. *J Vasc Surg*. 2009;49:15251531. 10.1016/j.jvs.2009.01.041
 41. Bown MJ, Jones GT, Harrison SC, Wright BJ, Bumpstead S, Baas AF, et al. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. *Am J Hum Genet*. 2011;89:619–627. 10.1016/j.ajhg.2011.10.002
 42. Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de Vries JP, et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. *Nat Genet*. 2010;42:692–697. 10.1038/ng.622
 43. Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. *Nat Genet*. 2008;40:217–224. 10.1038/ng.72
 44. Harrison SC, Smith AJ, Jones GT, Swerdlow DI, Rampuri R, Bown MJ, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. *Eur Heart J*. Published online before print October 30, 2012. 10.1093/eurheartj/ehs354. Available at: <http://eurheartj.oxfordjournals.org/content/early/2012/10/30/eurheartj.ehs354.long>. Accessed April 3, 2013.
 45. Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. *J Am Coll Cardiol*. 2012;60:722–729. 10.1016/j.jacc.2012.01.078
 46. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet*. 2011;6:333–338.
 47. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 2010;466:707–713. 10.1038/nature09270
 48. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. *Nat Rev Genet*. 2010;11:843–854. 10.1038/nrg2884
 49. Thorgerirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature*. 2008;452:638–642. 10.1038/nature06846
 50. McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, et al. The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies. *BMC Med Genomics*. 2011;4:13. 10.1186/1755–8794–4–13
 51. Folkersen L, van't Hooft F, Chernogubova E, Agardh HE, Hansson GK, Hedin U, et al. Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease. *Circ Cardiovasc Genet*. 2010;3:365–373. 10.1161/CIRCGENETICS.110.948935
 52. Hinterseher I, Erdman R, Donoso LA, Vrabec TR, Schworer CM, Lillvis JH, et al. Role of complement cascade in abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol*. 2011;31:1653–1660. 10.1161/ATVBAHA.111.227652
 53. Hinterseher I, Erdman R, Elmore JR, Stahl E, Pahl MC, Derr K, et al. Novel pathways in the pathobiology of human abdominal aortic aneurysms. *Pathobiology*. 2013;80:1–10. 10.1159/000339303
 54. Michel JB, Martin-Ventura JL, Egido J, Sakalihasan N, Treska V, Lindholt J, et al. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. *Cardiovasc Res*. 2011;90:18–27. 10.1093/cvr/cvq337
 55. Pincemail J, Defraigne JO, Cheramy-Bien JP, Dardenne N, Donneau AF, Albert A, et al. On the potential increase of the oxidative stress status in patients with abdominal aortic aneurysm. *Redox Rep*. 2012;17:139–144. 10.1179/1351000212Y.0000000012
 56. Ciborowski M, Teul J, Martin-Ventura JL, Egido J, Barbas C. Metabolomics with LC-QTOF-MS permits the prediction of disease stage in aortic abdominal aneurysm based on plasma metabolic fingerprint. *PLoS One*. 2012;7:e31982. 10.1371/journal.pone.0031982
 57. Martinez-Pinna R, Ramos-Mozo P, Madrigal-Matute J, Blanco-Colio LM, Lopez JA, Calvo E, et al. Identification of peroxiredoxin-1 as a novel biomarker of abdominal aortic aneurysm. *Arterioscler Thromb Vasc Biol*. 2011;31:935–943. 10.1161/ATVBAHA.110.214429
 58. Ramos-Mozo P, Madrigal-Matute J, Martinez-Pinna R, Blanco-Colio LM, Lopez JA, Camafeita E, et al. Proteomic analysis of polymorphonuclear neutrophils identifies catalase as a novel biomarker of abdominal aortic aneurysm: Potential implication of oxidative stress in abdominal aortic aneurysm progression. *Arterioscler Thromb Vasc Biol*. 2011;31:3011–3019. 10.1161/ATVBAHA.111.237537
 59. Ramos-Mozo P, Madrigal-Matute J, Vega de Ceniga M, Blanco-Colio LM, Meilhac O, Feldman L, et al. Increased plasma levels of NGAL, a marker of neutrophil activation, in patients with abdominal aortic aneurysm. *Atherosclerosis*. 2012;220:552–556. 10.1016/j.atherosclerosis.2011.11.023
 60. Ramos-Mozo P, Rodriguez C, Pastor-Vargas C, Blanco-Colio LM, Martinez-Gonzalez J, Meilhac O, et al. Plasma profiling by a protein array approach identifies IGFBP-1 as a novel biomarker of abdominal aortic aneurysm. *Atherosclerosis*. 2012;221:544–550. 10.1016/j.atherosclerosis.2012.01.009
 61. Ruperez FJ, Ramos-Mozo P, Teul J, Martinez-Pinna R, Garcia A, Malet-Martino M, et al. Metabolomic study of plasma of patients with abdominal aortic aneurysm. *Anal Bioanal Chem*. 2012;403:1651–1660. 10.1007/s00216–012-5982-y
 62. van der Meij E, Koning GG, Vriens PW, Peeter MF, Meijer CA, Kortekaas KE, et al. A clinical evaluation of statin pleiotropy: Statins selectively and dose-dependently reduce vascular inflammation. *PLoS One*.

- 2013;8:e53882. 10.1371/journal.pone.0053882
63. Onoda M, Yoshimura K, Aoki H, Ikeda Y, Morikage N, Furutani A, et al. Lysyl oxidase resolves inflammation by reducing monocyte chemoattractant protein-1 in abdominal aortic aneurysm. *Atherosclerosis*. 2010; 208:366–369. 10.1016/j.atherosclerosis.2009.07.036
 64. Pirianov G, Torsney E, Howe F, Cockerill GW. Rosiglitazone negatively regulates c-Jun N-terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms. *Atherosclerosis*. 2012;225:69–75. 10.1016/j.atherosclerosis.2012.07.034
 65. Torsney E, Pirianov G, Charolidi N, Shoreim A, Gaze D, Petrova S, et al. Elevation of plasma high-density lipoproteins inhibits development of experimental abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol*. 2012;32: 2678–2686. 10.1161/ATVBAHA.112.00009
 66. Lillis JH, Erdman R, Schworer CM, Golden A, Derr K, Gatalica Z, et al. Regional expression of HOXA4 along the aorta and its potential role in human abdominal aortic aneurysms. *BMC Physiol*. 2011;11:9. 10.1186/1472-6793-11-9
 67. Pahl MC, Derr K, Gabel G, Hinterseher I, Elmore JR, Schworer CM, et al. MicroRNA expression signature in human abdominal aortic aneurysms. *BMC Med Genomics*. 2012;5:25. 10.1186/1755-8794-5-25
 68. Nischan J, Gatalica Z, Curtis M, Lenk GM, Tromp G, Kuivaniemi H. Binding sites for ETS family of transcription factors dominate the promoter regions of differentially expressed genes in abdominal aortic aneurysms. *Circ Cardiovasc Genet*. 2009;2:565–572. 10.1161/CIRCGENETICS.108.843854
 69. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T, Group A. Effects of statin therapy on abdominal aortic aneurysm growth: A meta-analysis and meta-regression of observational comparative studies. *Eur J Vasc Endovasc Surg*. 2012;44:287–292. 10.1016/j.ejvs.2012.06.021
 70. Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. *Br J Surg*. 2011;98:346–353. 10.1002/bjs.7343
 71. Vega de Ceniga M. Commentary on "Effects of statin therapy on abdominal aortic aneurysm growth: A meta-analysis and meta-regression of observational comparative studies." *Eur J Vasc Endovasc Surg*. 2012;44: 293. 10.1016/j.ejvs.2012.06.024
 72. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. *Cochrane Database Syst Rev*. 2012; 9:CD009536.
 73. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: A population-based case-control study. *Lancet*. 2006;368:659–665. 10.1016/S0140-6736(06)69250-7
 74. Miyake T, Morishita R. Pharmacological treatment of abdominal aortic aneurysm. *Cardiovasc Res*. 2009;83:436–443. 10.1093/cvr/cvp155
 75. Malas MB, Freischlag JA. Interpretation of the results of OVER in the context of EVAR trial, DREAM, and the EUROSTAR registry. *Semin Vasc Surg*. 2010;23:165–169. 10.1053/j.semvascsurg.2010.05.009
 76. Holt PJ, Karthikesalingam A, Patterson BO, Ghatwary T, Hinchliffe RJ, Loftus IM, Thompson MM. Aortic rupture and sac expansion after endovascular repair of abdominal aortic aneurysm. *Br J Surg*. 2012; 99:1657–1664. 10.1002/bjs.8938
 77. Prenner SB, Turnbull IC, Malik R, Salloum A, Ellozy SH, Vouyouka AG, et al. Outcome of elective endovascular abdominal aortic aneurysm repair in octogenarians and nonagenarians. *J Vasc Surg*. 2010;51:1354–1359. 10.1016/j.jvs.2010.01.030
 78. Chadi SA, Rowe BW, Vogt KN, Novick TV, Harris JR, Derose G, Forbes TL. Trends in management of abdominal aortic aneurysms. *J Vasc Surg*. 2012;55:924–928. 10.1016/j.jvs.2011.10.094
 79. Kent KC, Crenshaw ML, Goh DL, Dietz HC. Genotype-phenotype correlation in patients with bicuspid aortic valve and aneurysm. *J Thorac Cardiovasc Surg*. 2012. Published before print October 24, 2012. 10.1016/j.jtcvs.2012.09.060. Available at: [http://www.jtcvsonline.org/article/S0022-5223\(12\)01214-7/abstract](http://www.jtcvsonline.org/article/S0022-5223(12)01214-7/abstract). Accessed April 3, 2013.
 80. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. *Circulation*. 2005;111:920–925. 10.1161/01.CIR.0000155623.48408.C5
 81. Hinton RB. Bicuspid aortic valve and thoracic aortic aneurysm: Three patient populations, two disease phenotypes, and one shared genotype. *Cardiol Res Pract*. 2012; 2012:926–975.
 82. Bonderman D, Gharebaghi-Schnell E, Wolleken G, Maurer G, Baumgartner H, Lang IM. Mechanisms underlying aortic dilatation in congenital aortic valve malformation. *Circulation*. 1999;99:2138–2143. 10.1161/01.CIR.99.16.2138
 83. Kurtovic S, Paloschi V, Folkersen L, Gotfries J, Franco-Cereceda A, Eriksson P. Diverging alternative splicing fingerprints in the transforming growth factor-beta signaling pathway identified in thoracic aortic aneurysms. *Mol Med*. 2011;17:665–675.
 84. Folkersen L, Wagsater D, Paloschi V, Jackson V, Petrini J, Kurtovic S, et al. Unraveling divergent gene expression profiles in bicuspid and tricuspid aortic valve patients with thoracic aortic dilatation: The ASAP study. *Mol Med*. 2011;17:1365–1373.
 85. Ikonomidis JS, Ruddy JM, Benton SM Jr, Arroyo J, Brinsa TA, Stroud RE, et al. Aortic dilatation with bicuspid aortic valves: Cusp fusion correlates to matrix metalloproteinases and inhibitors. *Ann Thorac Surg*. 2012;93:457–463. 10.1016/j.athoracsur.2011.09.057
 86. Faggiano E, Antiga L, Puppini G, Quarteroni A, Luciani GB, Vergara C. Helical flows and asymmetry of blood jet in dilated ascending aorta with normally functioning bicuspid valve. *Biomech Model Mechanobiol*. Published before print October 5, 2012. 10.1007/s10237-012-0444-1. Available at: <http://link.springer.com/article/10.1007%2Fs10237-012-0444-1>. Accessed April 3, 2013.
 87. Barker AJ, Markl M, Burk J, Lorenz R, Bock J, Bauer S, et al. Bicuspid aortic valve is associated with altered wall shear stress in the ascending aorta. *Circ Cardiovasc Imaging*. 2012;5:457–466. 10.1161/CIRCIMAGING.112.973370
 88. Girdauskas E, Disha K, Raisin HH, Secknus MA, Borger MA, Kuntze T. Risk of late aortic events after an isolated aortic valve replacement for bicuspid aortic valve stenosis with concomitant ascending aortic dilation. *Eur J Cardiothorac Surg*. 2012;42: 832–838. 10.1093/ejcts/ezs137
 89. McKellar SH, Michelena HI, Li Z, Schaff HV, Sundt TM, 3rd. Long-term risk of aortic events following aortic valve replacement in patients with bicuspid aortic valves. *Am J Cardiol*. 2010;106:1626–1633. 10.1016/j.amjcard.2010.07.043
 90. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardiothoracic Surgery (EACTS). *Eur J Cardiothorac Surg*. 2012;42:S1–S44. 10.1093/ejcts/ezs455
 91. Etz CD, Misfeld M, Borger MA, Luehr M, Strottdrees E, Mohr FW. Current indications for surgical repair in patients with bicuspid aortic valve and ascending aortic ectasia. *Cardiol Res Pract*. 2012;2012: 313–379.

92. Price J, De Kerchove L, Glineur D, Vanoverschelde JL, Noirhomme P, El Khoury G. Risk of valve-related events after aortic valve repair. *Ann Thorac Surg.* 2013;95:606–612. 10.1016/j.athoracsur.2012.07.016
93. Lederle FA, Freischlag JA, Kyriakides TC, Matsumura JS, Padberg FT Jr., Kohler TR, et al. Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. *N Engl J Med.* 2012;367:1988–1997. 10.1056/NEJMoa1207481
94. Sakalihasan N, Hustinx R, Limet R. Contribution of PET scanning to the evaluation of abdominal aortic aneurysm. *Semin Vasc Surg.* 2004;17:144–153. 10.1053/j.semvasc.2004.03.002
95. Sakalihasan N, Michel JB. Functional imaging of atherosclerosis to advance vascular biology. *Eur J Vasc Endovasc Surg.* 2009;37:728–734. 10.1016/j.ejvs.2008.12.024
96. Xu XY, Borghi A, Nchimi A, Leung J, Gomez P, Cheng Z, et al. High levels of 18F-FDG uptake in aortic aneurysm wall are associated with high wall stress. *Eur J Vasc Endovasc Surg.* 2010;39:295–301. 10.1016/j.ejvs.2009.10.016
97. Reeps C, Essler M, Pelisek J, Seidl S, Eckstein HH, Krause BJ. Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. *J Vasc Surg.* 2008;48:417–423. 10.1016/j.jvs.2008.03.059
98. Truijers M, Kurvers HA, Bredie SJ, Oyen WJ, Blankensteijn JD. In vivo imaging of abdominal aortic aneurysms: Increased FDG uptake suggests inflammation in the aneurysm wall. *J Endovasc Ther.* 2008;15:462–467. 10.1583/08–2447.1
99. Defawe OD, Hustinx R, Defraigne JO, Limet R, Sakalihasan N. Distribution of F-18 fluorodeoxyglucose (F-18 FDG) in abdominal aortic aneurysm: High accumulation in macrophages seen on PET imaging and immunohistology. *Clin Nucl Med.* 2005;30:340–341. 10.1097/01.rlu.0000159681.24833.95
100. Tierney AP, Callanan A, McGloughlin TM. In vivo feasibility case study for evaluating abdominal aortic aneurysm tissue properties and rupture potential using acoustic radiation force impulse imaging. *J Mech Behav Biomed Mater.* 2011;4:507–513. 10.1016/j.jmbbm.2010.12.017
101. Tierney AP, Callanan A, McGloughlin TM. Use of regional mechanical properties of abdominal aortic aneurysms to advance finite element modeling of rupture risk. *J Endovasc Ther.* 2012;19:100–114. 10.1583/11–3456.1
102. Tierney AP, Dumont DM, Callanan A, Trahey GE, McGloughlin TM. Acoustic radiation force impulse imaging on ex vivo abdominal aortic aneurysm model. *Ultrasound Med Biol.* 2010;36:821–832. 10.1016/j.ultrasmedbio.2010.02.018
103. Martufi G, Auer M, Roy J, Swedenborg J, Sakalihasan N, Panuccio G, Gasser CT. Growth of small abdominal aortic aneurysms: A multidimensional approach. *J Vasc Surg.* In press.

Cite this article as: Kuivaniemi H, Sakalihasan N, Lederle FA, Jones GT, Defraigne J-O, Labropoulos N, Legrand V, Michel J-B, Nienaber C, Radermecker MA, Elefteriades JA. New Insights Into Aortic Diseases: A Report From the Third International Meeting on Aortic Diseases (IMAD3). *Aorta* 2013;1(1):23–39. DOI: <http://dx.doi.org/10.12945/j.aorta.2013.13.006>

EDITOR'S COMMENTS

Dr. Roberto Chiesa, Professor, University di Bologna, Italy

The IMAD 3 (3rd International Meeting on Aortic Disease) contributions on current research and treatment of aortic disease are discussed in this paper. The authors analyzed recent discoveries on epidemiology, genetics, pathophysiology and medical and surgical treatment of aortic disease and valve pathology.

Connective tissue disorders resulting in thoracic aortic involvement currently represent one of the most complex research issues in medicine, due to multimodal manifestations related to phenotypic and genotypic heterogeneity. The IMAD reports conclude that multigenic mutations, particularly on TGFB genes, need to be analyzed in patients as well as with correlations to experimental animal models.

Open repair of arch and thoracoabdominal aortic aneurysms is currently the best therapeutic option, using contemporary adjuncts addressing brain, spinal cord, and visceral protection. Deep hypothermic circulatory arrest, with or without antegrade selective

cerebral perfusion, can be useful for brain protection during aortic arch surgery. During thoracoabdominal aortic repair, the use of left heart bypass seems to be mandatory, along with cerebro-spinal fluid drainage and reimplantation of key intercostal arteries, with or without evoked potential monitoring and mild hypothermia.

Regarding abdominal aortic aneurysm (AAA), the paper reported a significant overall mortality reduction achieved using a combination of elective repair, supplemented with statin and antihypertensive drug administration. The future will provide further results regarding the impact of genetic mutations, inflammation responses, and oxidative stress on the aortic wall in patients with AAA. Detectable serum or plasma biomarkers will help identify patients with AAA, monitor growth, and predict rupture. The protective role of statins on the aortic wall is currently discussed. Recent improvements in vascular disease imaging can offer optimal anatomical and morphological information, and the latest research focused on PET imaging will provide data about inflammation and oxidative stress.

Comparison between EVAR and Open Repair is discussed, concluding that early benefits of EVAR sig-

nificantly disappear over time due to the 20% rate of secondary intervention and the 1% rate of index aneurysm rupture during follow up. Elective EVAR remains the procedure of choice in elderly patients or those with severe comorbidities.

The correlation between bicuspid aortic valve and ascending aortic pathology is emphasized, and two hypotheses are described: (1) The “intrinsic genetic” aneurysm predisposition secondary to specific aortic and valve features related to neural crest cell changes, and (2) The “stress induced aortopathy” secondary

to abnormal flow patterns and parietal stress in specific aortic segments. While the benefits of medical therapy in aortic valve disease are limited, surgical repair continues to offer good results. TAVI seems to be indicated in high-risk patients.

This article provides a wide range of interesting topics related to aortic and valve disease and represents an appreciable informational update, based on interchange and debate between the distinguished clinicians and scientists participating in the IMAD 3 symposium.